Article
Phase II study of S-1 and irinotecan combination therapy in EGFR-mutated non-small cell lung cancer resistant to epidermal growth factor receptor tyrosine kinase inhibitor: North Japan Lung Cancer Study Group Trial 0804 (NJLCG0804).
Medical oncology (Northwood, London, England) - 16 Aug 2022
Nakamura Atsushi, Harada Masao, Watanabe Kana, Harada Toshiyuki, Inoue Akira, Sugawara Shunichi
Abstract excerpt
We conducted a multicenter phase II trial to evaluate the efficacy and safety of S-1 and irinotecan combination therapy in patients with epidermal growth factor receptor-mutated non-small-cell lung cancer treated with epidermal growth factor receptor tyrosine kinase inhibitors. Epidermal growth factor receptor-mutated non-small-cell lung cancer patients treated with epidermal growth factor receptor tyrosine...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.